Abstract
BACKGROUND AND PURPOSE-Interactions between excitotoxic, inflammatory, and apoptotic pathways determine outcome in hypoxic-ischemic brain damage. The transcription factor NF-μ°B has been suggested to enhance brain damage via stimulation of cytokine production. There is also evidence that NF-μ°B activity is required for neuronal survival. We used the NF-μ°B inhibitor NBD, coupled to TAT to facilitate cerebral uptake, to determine the neuroprotective capacity of NF-μ°B inhibition in neonatal hypoxia-ischemia (HI) and to identify its contribution to cerebral inflammation and damage. METHODS-Brain damage was induced in neonatal rats by unilateral carotid artery occlusion and hypoxia and analyzed immunohistochemically; NF-μ°B activity was analyzed by EMSA. We analyzed cytokine mRNA levels and activation of apoptotic pathways by Western blotting. In vitro effects of TAT-NBD were determined in a neuronal cell line. RESULTS-Inhibition of cerebral NF-μ°B activity by TAT-NBD had a significant neuroprotective effect; brain damage was reduced by more than 80% with a therapeutic window of at least 6 hours. In contrast to earlier suggestions, the protective effect of TAT-NBD did not involve suppression of early cytokine upregulation after HI. Moreover, NF-μ°B inhibition prevented HI-induced upregulation and nuclear as well as mitochondrial accumulation of p53, prevented mitochondrial cytochrome-c release and activation of caspase-3. Finally, TAT-NBD could directly increase neuronal survival because TAT-NBD was sufficient to inhibit death in a neuronal cell line. A nonactive mutant peptide did not have any effect. CONCLUSIONS-Inhibition of NF-μ°B has strong neuroprotective effects that involve downregulation of apoptotic molecules but are independent of inhibition of cytokine production.
Original language | English |
---|---|
Pages (from-to) | 2129-2137 |
Number of pages | 9 |
Journal | Stroke |
Volume | 39 |
Issue number | 7 |
DOIs | |
Publication status | Published - 1 Jul 2008 |
Keywords
- Inflammation
- Neonatal
- Neuroprotection
- Nuclear factor?kappa-B